Evidence map›Paper›PMID 37995329›Full record

Observational studyRevista medica del Instituto Mexicano del Seguro Social2023

[Subtle and subclinical neurological findings in patients with SARS-CoV-2].

Daniel Arturo Martínez-Piña, Daniel San Juan-Orta, Edith González-Guevara, Clara Elena Vázquez-Díaz, Martha Alicia Hernández-González, José Octavio Sosa-Ramos

Abstract readEnglish AbstractObservational Study
In one paragraph

Observational study in Revista medica del Instituto Mexicano del Seguro Social, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daniel Arturo Martínez-PiñaSecretaría de Salud, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Servicio de Neurología. Ciudad de México, México.ORCID 0000-0003-0271-9150
Daniel San Juan-OrtaSecretaría de Salud, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Servicio de Epilepsia. Ciudad de México, México.ORCID 0000-0001-6685-5851
Edith González-GuevaraSecretaría de Salud, Instituto de Neurología y Neurocirugía Manuel Velasco Suárez, Laboratorio de Neurofarmacología Molecular y Nanotecnología. Ciudad de México, México.ORCID 0000-0002-8682-6895
Clara Elena Vázquez-DíazInstituto Mexicano del Seguro Social, Unidad Médica de Alta Especialidad No. 1, Servicio de Neurología y Neurofisiología. León, Guanajuato, México.ORCID 0000-0001-5471-9393
Martha Alicia Hernández-GonzálezInstituto Mexicano del Seguro Social, Centro Médico Nacional del Bajío, Hospital de Especialidades No. 1, División de Investigación en Salud. León, Guanajuato, México.ORCID 0000-0002-6903-2233
José Octavio Sosa-RamosInstituto Mexicano del Seguro Social, Hospital General de Zona N° 58, Servicio de Medicina Interna. León, Guanajuato, México.ORCID 0000-0002-2555-6684

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There are severe neurological conditions in patients with COVID-19, such as: cerebrovascular disease, Guillain-Barré syndrome, encephalitis, acute hemorrhagic necrotizing encephalopathy and myelitis. Objective: We describe that the patient with SARS-CoV 2 with respiratory symptoms has subtle or subclinical neurological manifestations. Material and methods: Observational, cross-sectional, analytical study, which included patients aged 18-65 years with respiratory symptoms and a confirmed diagnosis of COVID-19. Intubated patients with chronic neurodegenerative diseases or pre-existing neurological compromise were excluded. Semiology of the headache and neurological examination were performed; Serum levels of glucose, protein, electrolytes, lactate, C-reactive protein, lactic dehydrogenase, and D-dimer were measured. Cerebrospinal fluid (CSF) analysis and electroencephalogram (EEG) were also performed in patients who accepted the risks. Results: A high prevalence of subtle neurological manifestations was found in patients with COVID-19 with only a respiratory clinical picture. Headache, anosmia, dysgeusia, and hypopalesthesia predominated in the early stages, with frequent abnormal findings in the CSF (>70%) and less frequently in the EEG (<20%). Conclusions: Headache, anosmia, dysgeusia and hypoesthesia were frequent at the beginning of the infection, together with abnormal findings in CSF and EEG, without other neurological symptoms or neurological disease.

Indexed as

COVID-19Nervous System DiseasesAnosmiaCross-Sectional StudiesDysgeusiaHeadacheHumansSARS-CoV-2CefaleaCerebrospinal FluidElectroencefalogramaElectroencephalogramHeadacheLíquido CefalorraquídeoNeurological SymptomsSARS-CoV-2Síntomas Neurológicos

Identifiers

PMID37995329
PMCPMC10712932

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.